Sharon Shacham - Feb 17, 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
Chief Scientific Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Sharon Shacham
Stock symbol
KPTI
Transactions as of
Feb 17, 2022
Transactions value $
-$220,246
Form type
4
Date filed
2/22/2022, 03:15 PM
Previous filing
Feb 9, 2022
Next filing
Mar 2, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$110K -9.09K -0.99% $12.12 904K Feb 17, 2022 Direct F1, F2
transaction KPTI Common Stock Sale -$110K -9.08K -1.28% $12.12 699K Feb 17, 2022 By Spouse F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
F3 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.
F4 The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.